Toxoplasmosis

Toxoplasmosis is a zoonotic protozoal infection caused by the obligate intracellular apicomplexan parasite Toxoplasma gondii. In veterinary medicine, the domestic cat (Felis catus) is the definitive host, while a wide range of warm-blooded animals, including dogs, humans, and livestock, serve as intermediate hosts. The disease manifests in two distinct phases: an acute proliferative phase characterized by tachyzoite dissemination and tissue necrosis, and a chronic phase marked by bradyzoite-containing tissue cysts, particularly in neural and muscular tissues. Clinical toxoplasmosis in dogs and cats can range from subclinical infection to severe multisystemic disease, with a predilection for the central nervous system, respiratory tract, liver, and eyes. The disease is of significant public health importance due to its zoonotic potential, especially in immunocompromised individuals and pregnant women.

The causative agent is Toxoplasma gondii, a coccidian protozoan belonging to the phylum Apicomplexa. The parasite has a complex life cycle involving sexual reproduction exclusively in the feline intestinal epithelium, leading to the shedding of unsporulated oocysts in feces. Oocysts sporulate in the environment within 1-5 days and become infective. Intermediate hosts acquire infection by ingesting sporulated oocysts from contaminated soil, water, or food, or by consuming tissue cysts (bradyzoites) in raw or undercooked meat. Transplacental transmission occurs in both cats and dogs, and lactational transmission has been reported. The parasite exists in three infectious stages: sporozoites (in oocysts), tachyzoites (rapidly dividing, responsible for acute disease), and bradyzoites (slowly dividing, within tissue cysts). Virulence factors include the ability to invade host cells actively, modulation of host immune responses, and the formation of tissue cysts that evade immune surveillance. Genotypes of T. gondii (Types I, II, III, and atypical) vary in pathogenicity; Type II is most common in Europe and North America, while atypical strains are associated with severe outbreaks.

Toxoplasmosis has a worldwide distribution, with seroprevalence rates varying by geographic region, climate, and management practices. In domestic cats, seroprevalence ranges from 30% to 50% in some regions, with higher rates in outdoor and feral cats. Dogs have lower seroprevalence (10-30%) due to their less definitive role in the life cycle. Clinical disease is relatively uncommon compared to seropositivity, as most infections are subclinical. Young animals (especially kittens and puppies) are more susceptible to severe disease due to immature immune systems. Immunosuppressed animals, including those with feline leukemia virus (FeLV), feline immunodeficiency virus (FIV), or those receiving immunosuppressive drugs, are at increased risk. Certain breeds may have genetic predispositions, but no specific breed predilection is well-documented. Geographic variation exists, with higher prevalence in humid, warm climates where oocyst survival is enhanced. Seasonal patterns may reflect increased feline reproduction and outdoor activity in spring and fall.

After ingestion, sporozoites or bradyzoites invade the intestinal epithelium and transform into tachyzoites, which disseminate hematogenously and lymphatically to various tissues. Tachyzoites actively invade nucleated cells, forming a parasitophorous vacuole where they replicate by endodyogeny. This leads to cell lysis, tissue necrosis, and an intense inflammatory response characterized by neutrophils, macrophages, and lymphocytes. The host immune response, particularly cell-mediated immunity (Th1 response with IFN-gamma and IL-12), is crucial in controlling tachyzoite proliferation. In immunocompetent animals, the infection is typically contained, and tachyzoites convert to bradyzoites, forming tissue cysts, especially in the brain, skeletal muscle, and myocardium. These cysts persist for the life of the host and can reactivate if immunity wanes. In immunocompromised animals, uncontrolled tachyzoite replication causes multifocal necrosis in the liver, lungs, central nervous system, and other organs. The pathogenesis of clinical signs involves direct cytolytic damage, inflammatory cytokine release, and secondary complications such as disseminated intravascular coagulation (DIC) and acute respiratory distress syndrome (ARDS). In the eye, toxoplasmosis causes retinochoroiditis due to retinal cell destruction and inflammation.

Intrinsic factors include age (neonates and juveniles are more susceptible), genetic immune deficiencies, and concurrent immunosuppressive diseases such as FeLV, FIV, and canine distemper virus. Extrinsic factors include poor sanitation, hunting behavior in cats (increasing exposure to infected prey), feeding raw or undercooked meat, and overcrowding in shelters. Immunosuppressive therapies, such as glucocorticoids or cyclosporine, can precipitate clinical toxoplasmosis in latently infected animals. Stress, pregnancy, and malnutrition may also increase susceptibility. In dogs, co-infection with other pathogens (e.g., Ehrlichia, Babesia) can exacerbate disease.

Clinical signs vary depending on the species, age, immune status, and organ systems involved. In cats, acute toxoplasmosis often presents with fever, lethargy, anorexia, and dyspnea due to pulmonary involvement. Hepatic signs include icterus, vomiting, and diarrhea. Neurological signs include seizures, ataxia, tremors, cranial nerve deficits, and behavioral changes. Ocular signs include uveitis, retinochoroiditis, and blindness. In dogs, similar signs are seen, with a higher incidence of neuromuscular disease (polymyositis, polyradiculoneuritis) presenting as muscle weakness, stiff gait, and proprioceptive deficits. Respiratory signs (pneumonia) and gastrointestinal signs (pancreatitis, hepatitis) are also common. Neonates may develop fatal systemic disease with high mortality. Chronic infection is usually asymptomatic, but reactivation can cause recrudescence of clinical signs.

Differential diagnoses include: (1) Canine distemper virus infection – presents with respiratory, gastrointestinal, and neurological signs; distinguished by viral antigen detection or serology, and characteristic intracytoplasmic inclusion bodies. (2) Feline infectious peritonitis (FIP) – causes fever, effusions, and granulomatous lesions; diagnosed by coronavirus serology, Rivalta test, and histopathology. (3) Neosporosis (Neospora caninum) – similar neuromuscular signs in dogs; differentiated by serology (specific antibodies) and PCR, and absence of oocyst shedding in cats. (4) Bacterial sepsis – can cause fever, shock, and multi-organ failure; diagnosed by blood cultures and response to antibiotics. (5) Lymphoma – may present with mass lesions and systemic signs; diagnosed by cytology/histopathology and immunophenotyping. (6) Immune-mediated hemolytic anemia (IMHA) – causes icterus and anemia; diagnosed by Coombs test and spherocytosis. (7) Hepatic lipidosis in cats – causes icterus and anorexia; diagnosed by hepatic biopsy and ultrasonography. (8) Toxocariasis – causes respiratory and hepatic signs; diagnosed by fecal flotation and serology. (9) Cryptococcosis – causes respiratory and neurological signs; diagnosed by cytology (yeast organisms) and antigen testing. (10) Systemic mycoses (e.g., histoplasmosis) – cause fever, weight loss, and organomegaly; diagnosed by cytology, histopathology, and fungal culture.

The diagnostic approach begins with a thorough history (including outdoor access, raw meat diet, immunosuppressive therapy) and physical examination. Initial screening includes complete blood count (CBC), serum biochemistry panel, and urinalysis. If toxoplasmosis is suspected, specific serological testing is performed: IgM and IgG antibodies via ELISA or immunofluorescence assay (IFA). A four-fold rise in IgG titers over 2-4 weeks or the presence of IgM antibodies indicates recent or active infection. However, serology alone cannot confirm clinical disease, as many healthy animals are seropositive. Definitive diagnosis requires demonstration of the organism or its DNA. PCR testing on blood, cerebrospinal fluid (CSF), aqueous humor, bronchoalveolar lavage (BAL) fluid, or tissue aspirates is highly sensitive and specific. Cytological or histopathological examination of affected tissues (e.g., liver, lung, brain) may reveal tachyzoites or tissue cysts. In cats, fecal flotation can detect oocysts, but shedding is transient and intermittent. Imaging (thoracic radiographs, abdominal ultrasound, MRI of the brain) helps identify organ involvement. A diagnostic algorithm would proceed from non-specific tests to specific serology/PCR, and if necessary, invasive sampling for cytology/histopathology.

Hematology: Non-regenerative anemia, leukopenia (neutropenia, lymphopenia) in acute phase, followed by leukocytosis with left shift. Thrombocytopenia may occur. Serum biochemistry: Elevated liver enzymes (ALT, AST, ALP), hyperbilirubinemia, hypoalbuminemia, and increased creatinine kinase (CK) in cases of myositis. Azotemia may indicate renal involvement. Electrolyte imbalances (hyponatremia, hyperkalemia) can occur with gastrointestinal losses. Urinalysis: Proteinuria, bilirubinuria, and casts may be present. Blood gas analysis may reveal metabolic acidosis or respiratory alkalosis. Specific biomarkers: Elevated serum amyloid A (SAA) and C-reactive protein (CRP) indicate inflammation. Serology: IgM antibodies appear within 1-2 weeks post-infection and decline over months; IgG antibodies rise later and persist for years. A positive IgM or a four-fold increase in IgG is suggestive of active infection. PCR: Detection of T. gondii DNA in blood, CSF, or tissue is confirmatory. In CSF, analysis may show increased protein and mixed mononuclear pleocytosis.

Thoracic radiographs: Interstitial or alveolar patterns, often with a cranioventral distribution, consistent with pneumonia. In severe cases, pleural effusion may be present. Abdominal ultrasonography: Hepatomegaly, splenomegaly, lymphadenopathy, and diffuse hyperechogenicity of the liver. Focal abscesses or granulomas may be seen. Computed tomography (CT) of the brain: May reveal multifocal contrast-enhancing lesions, edema, or mass effects. Magnetic resonance imaging (MRI): More sensitive for detecting cerebral and spinal cord lesions, showing T2-hyperintense, T1-hypointense lesions with variable contrast enhancement. Ocular ultrasonography: May show retinal detachment or vitreous opacities in cases of retinochoroiditis. Echocardiography: In myocarditis, may show reduced contractility and wall motion abnormalities.

Cytology: Fine-needle aspirates of lymph nodes, liver, or lung may show tachyzoites (crescent-shaped organisms) within macrophages or free in the background. In CSF, tachyzoites are rarely seen but may be detected with careful examination. Histopathology: Tissues (brain, liver, lung, heart) show multifocal necrosis with mixed inflammatory infiltrates (neutrophils, macrophages, lymphocytes). Tissue cysts (bradyzoites) are round to oval, 10-200 μm, and may be found in the brain, muscle, and other organs. Special stains such as immunohistochemistry (IHC) using anti-T. gondii antibodies can confirm the presence of the organism. In the eye, retinochoroiditis with necrosis and granulomatous inflammation is characteristic.

The primary treatment for clinical toxoplasmosis is antiprotozoal therapy. The classic regimen is a combination of pyrimethamine (0.5-1 mg/kg PO q24h) and a sulfonamide such as sulfadiazine (30-60 mg/kg PO q12h) or trimethoprim-sulfamethoxazole (15-30 mg/kg PO q12h). Clindamycin (10-20 mg/kg PO/IV q12h) is also effective and is often preferred in cats due to fewer side effects. Treatment duration is typically 2-4 weeks, but may be extended in immunocompromised animals. Supportive care includes fluid therapy, nutritional support (e.g., feeding tubes in anorexic cats), antiemetics (e.g., maropitant 1 mg/kg SC q24h), and hepatoprotectants (e.g., S-adenosylmethionine). In cases of severe inflammation, such as uveitis or encephalitis, systemic glucocorticoids (e.g., prednisolone 0.5-2 mg/kg PO q24h) may be added after antiprotozoal therapy has been initiated to reduce inflammation. However, corticosteroids should be used cautiously as they can exacerbate the infection. For ocular toxoplasmosis, topical glucocorticoids and atropine may be used. In dogs with neuromuscular disease, physical rehabilitation may be beneficial. Surgical intervention is rarely indicated, except for drainage of abscesses if present.

The prognosis for clinical toxoplasmosis is guarded to good, depending on the severity of organ involvement and the immune status of the animal. With prompt and appropriate treatment, many animals recover, especially if the disease is localized. However, severe pulmonary, hepatic, or neurological involvement carries a poorer prognosis, with mortality rates up to 50% in some reports. Immunocompromised animals have a higher risk of treatment failure and relapse. Chronic infection is lifelong, and reactivation can occur. Negative prognostic indicators include severe respiratory distress, marked elevation of liver enzymes, neurological deficits, and lack of response to therapy within 48-72 hours.

Re-evaluation should occur 2-4 weeks after initiation of treatment to assess clinical response and monitor for adverse drug effects (e.g., bone marrow suppression from pyrimethamine). Serial CBC and biochemistry panels are recommended. Serological monitoring (IgM and IgG titers) can be performed to assess response, but titers may not correlate with clinical cure. In animals with ocular or neurological signs, repeat ophthalmic and neurological examinations are indicated. Long-term follow-up every 3-6 months is advised for immunocompromised animals. Owners should be educated about zoonotic risks, including proper hygiene and preventing cats from hunting.

Pearls: (1) In cats, toxoplasmosis is a common cause of uveitis; always consider it in cases of anterior uveitis. (2) Clindamycin is the drug of choice in cats due to its efficacy and safety profile. (3) A positive IgM titer or a four-fold rise in IgG is more indicative of active infection than a single high IgG titer. (4) PCR on aqueous humor can be diagnostic in ocular toxoplasmosis. Pitfalls: (1) Do not rely solely on serology for diagnosis, as many healthy animals are seropositive. (2) Avoid using corticosteroids without concurrent antiprotozoal therapy, as they can worsen the infection. (3) Do not overlook the possibility of co-infections (e.g., FeLV/FIV) in cats with toxoplasmosis. (4) In dogs, neosporosis is a common differential that requires different treatment (clindamycin but not pyrimethamine).

Based on Plumb's Veterinary Drug Handbook, the following protocols are recommended: (1) Clindamycin hydrochloride: 10-20 mg/kg PO, IV, IM q12h for 2-4 weeks. In cats, oral administration is preferred; IV administration may cause vomiting. (2) Pyrimethamine: 0.5-1 mg/kg PO q24h, combined with sulfadiazine (30-60 mg/kg PO q12h) or sulfadimethoxine (15-30 mg/kg PO q24h). Folic acid (5 mg/day) may be supplemented to prevent bone marrow suppression. (3) Trimethoprim-sulfamethoxazole: 15-30 mg/kg PO q12h for 2-4 weeks. (4) For ocular disease, topical prednisolone acetate 1% and atropine 1% may be used, along with systemic antiprotozoals. (5) In severe inflammatory disease, prednisolone: 0.5-2 mg/kg PO q24h, tapering over 2-4 weeks. (6) Supportive drugs: Maropitant (1 mg/kg SC q24h) for vomiting; S-adenosylmethionine (20 mg/kg PO q24h) for hepatic support; and fluid therapy with balanced crystalloids (e.g., Lactated Ringer's solution) at maintenance rates (60-100 ml/kg/day in cats, 40-60 ml/kg/day in dogs). Dosages should be adjusted in renal or hepatic impairment. Contraindications: Pyrimethamine is contraindicated in pregnant animals due to teratogenic effects. Clindamycin may cause gastrointestinal upset. Drug interactions: Sulfonamides may potentiate the effects of warfarin and methotrexate.

Key studies and consensus guidelines: (1) The American Association of Feline Practitioners (AAFP) and the European Advisory Board on Cat Diseases (ABCD) have published guidelines on feline toxoplasmosis, recommending clindamycin as the first-line treatment. (2) A study by Lappin et al. (1992) demonstrated that clindamycin at 12.5 mg/kg q12h for 4 weeks was effective in treating experimental feline toxoplasmosis. (3) A retrospective study by Dubey et al. (2009) reported that clinical toxoplasmosis in cats is often associated with immunosuppressive diseases. (4) In dogs, a study by Barber and Trees (1996) showed that clindamycin is effective in treating neosporosis, but toxoplasmosis is less common. (5) The use of PCR for diagnosis has been validated in several studies, showing high sensitivity and specificity. (6) A meta-analysis by Montoya and Liesenfeld (2004) on human toxoplasmosis supports the use of pyrimethamine-sulfadiazine, but veterinary data are extrapolated. (7) The ABCD guidelines recommend screening cats for FeLV/FIV in cases of toxoplasmosis. (8) Recent research on the zoonotic potential emphasizes the importance of preventing environmental contamination with oocysts.